Amsterdam (ots/PRNewswire) - Data presented at the 2006 European League Against Rheumatism (EULAR) Annual Congress in Amsterdam show that 3 years of treatment with the selective co-stimulation modulator abatacept, maintains improvements in Rheumatoid Arthritis (RA) symptoms, physical function, disease activity ...
Amsterdam (ots/PRNewswire) - New data presented at the 2006 European League Against Rheumatism (EULAR) Annual Congress from the one-year open label extension of the 6-month ATTAIN trial (Abatacept Trial in Treatment of Anti-TNF INadequate responders)[1] in which all patients were treated with abatacept, a ...
Basel, Switzerland (ots/PRNewswire) - The US approval of TMC114 (darunavir), a new boosted protease inhibitor (PI), provides the opportunity to build a potent new treatment combination with the fusion inhibitor FUZEON (enfuvirtide) that can successfully combat the HIV virus in treatment resistant patients. ...
Basel, Switzerland and Amsterdam (ots/PRNewswire) - - First RA Drug to Achieve These Results in Patients With an Inadequate Response to Currently Available Treatments New data presented at the EULAR meeting (European League Against Rheumatism) show for the first time that MabThera (rituximab), a unique B cell targeted therapy, is able to significantly ...
- Further Information can bo downloaded at 18.00 hrs on: http://www.presseportal.ch/de/story.htx?firmaid=100010455&lang=2 - Basel (ots) - The metropolitan areas of Western Europe benefited disproportionately from the dot.com boom in the second ...
The European Science Foundation (ESF)
Brussels (ots/PRNewswire) - - Europe's Experts in the Field Will Hear the Plan and Discuss the Recommendations at Their Annual Meeting in Amsterdam this Week. The world's largest meeting of experts in rheumatic diseases will today hear and debate calls for a pan-European approach to prioritise and combine ...
Basel, Switzerland (ots/PRNewswire) - - Newest HIV Drug Works Better in Combination With FUZEON(R) The emergence of new HIV treatments, such as boosted protease inhibitors (PI), has led to a change in treatment goals for people living with drug-resistant HIV. Up until recently, it has been reluctantly ...
Shire Pharmaceuticals Group Plc
Basingstoke, England (ots/PRNewswire) - - First Human Cell Line-Derived Erythropoietin Research Reported BASINGSTOKE, England, June 16 /PRNewswire/ -- - Abstract Numbers: 562 and 576 Effective treatment of anaemia in patients suffering from chronic kidney disease (CKD)(x) is possible with the first erythropoietin product produced in a human cell ...
Mental Health Research Institute and Monash University of Victoria, Australia
Victoria, Australia (ots/PRNewswire) - A new study published by physicians from the Mental Health Research Institute and Monash University of Victoria, Australia, showed that all atypical antipsychotics studied were equally efficacious when used at optimal doses as primary medication for inpatients with acute ...
Spanish Society of Hypertension
Madrid, Spain (ots/PRNewswire) - - Caduet, Single-Pill Amlodipine and Atorvastatin Combination, Helps Patients Reduce Calculated Risk for a Fatal CV Event by 29 to 52 Percent Results from the JEWEL programme show that single-pill amlodipine/atorvastatin therapy, also known as Caduet, is an effective ...
Research Triangle Park, North Carolina (ots/PRNewswire) - - Multinational Clinical Trials Service Provider of the Year and Multinational CRO of the Year Quintiles Transnational Corp. today announced that its Quintiles East Asia subsidiary has been named the Asia Pacific region's Multinational Clinical Trials Service Provider of the Year and Multinational CRO of the Year by the consulting firm Frost ...
Toronto, Canada (ots/PRNewswire) - - The Increase of OPG Expression Explains the Uncoupling Effect of Protelos(R) on Bone Metabolism Exciting new data presented at the World Congress on Osteoporosis further the understanding of the unique dual mode of action of the anti-osteoporotic agent Protelos(R) ...
Leeds, England (ots/PRNewswire) - - Significant Response Rates and Manageable Side Effects Also Exhibited In Poor-Prognosis and Difficult-to-Treat Patients According to interim data from a new international Phase III study called CAM 307, previously untreated patients with progressive B-cell chronic ...
Basel, Switzerland (ots/PRNewswire) - A new study(1) suggests that treatment with the combination of the innovative cancer drugs Avastin (bevacizumab) and Tarceva (erlotinib) or Avastin with chemotherapy, improves progression-free survival in patients with recurrent or refractory non-small cell lung cancer ...
Atlanta, Georgia (ots/PRNewswire) - - 86% Rate of Tumour Control in myxoid liposarcomas - Correlation Between DNA Repair Gene Expression and Response Rate in Sarcomas - 78% Rate of Tumour Control in Platinum Pretreated Ovarian Cancer Patients PharmaMar highlights the results of three important studies out of 10 presented on Yondelis(R) at the Annual ...
Atlanta (ots/PRNewswire) - - Enrolment to a Pivotal Phase III Study of ZD6474 in Advanced Non-Small Cell Lung Cancer (NSCLC) is Also Underway AstraZeneca today announced at the annual meeting of the American Society of Clinical Oncology (ASCO) further results of two key Phase II studies of the novel ...
Basel, Switzerland (ots/PRNewswire) - - Real World Practice Confirms Avastin's Efficacy and Safety in Advanced Colorectal Cancer New data from 4,000 patients show that Avastin (bevacizumab rhuMAb-VEGF) enables patients with advanced colorectal cancer (CRC) to live longer without progression of their ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Company has signed an agreement with Lux Biosciences, Inc. of Jersey City, New Jersey granting Lux Biosciences worldwide rights to develop and commercialize Isotechnika's lead drug, ISA247 for the treatment and prophylaxis of all ophthalmic diseases. ISA247 is a novel calcineurin ...
Toronto (ots/PRNewswire) - - For Healthcare and Medical Reporters (non-US and non-UK) The results of a pivotal study confirm the potential of quetiapine fumarate (SEROQUEL) as a monotherapy (treatment with a single antipsychotic medicine) for acute bipolar depression. Quetiapine is an atypical ...
Ingelheim, Germany (ots/PRNewswire) - - Not for Distribution or Publication in the United States New omnibus data from the largest global survey due to be published, conducted on the epidemiology of constipation, were presented today at the Digestive Disease Week congress in Los Angeles. The survey, sponsored by Boehringer Ingelheim, offers new insights into the incidence of constipation and shows that ...
Ingelheim, Germany (ots/PRNewswire) - - For Healthcare Professional and Consumer Journalists - Not for Distribution to USA Media - Survey Shows 25% of World's Population Suffer From Common and Distressing Ailment That can be Effectively Treated New data presented at the premier international gastroenterology congress Digestive Disease Week (DDW) 2006 ...
San Diego, California (ots/PRNewswire) - - For Accredited International Healthcare Journalists Only - Management of Exacerbations `Crucial' to Reduce COPD Mortality Survey results from the `Time to Live' report, presented today at the American Thoracic Society International Congress, show over two thirds of primary care physicians (66%) fear COPD will be ...
European Hematlogy Association
Rotterdam, Netherlands (ots/PRNewswire) - - RAI CONVENTION CENTRE, AMSTERDAM Presentation of results of groundbreaking hematological research in the fields of donor stem-cell transplantation and thrombosis The 11th Congress of the European Hematology Association (EHA) is being held from June 15 to 18 ...
Natick, Massachusetts and Paris (ots/PRNewswire) - - New Second-Generation Training Center in Brussels to Help Medical Professionals Advance Standard of Patient Care Boston Scientific Corporation (NYSE: BSX) today announced plans for the construction of a new state-of-the art medical training facility in ...
Somerville, New Jersey (ots/PRNewswire) - ETHICON Women's Health & Urology announced today that it received CE Mark approval in Europe to market the GYNECARE TVT SECUR(i) System for female stress urinary incontinence (SUI). This new mid-urethral sling device maintains many of the key elements that made GYNECARE TVT the gold standard in SUI surgery, and optimizes ...
Natick, Massachusetts (ots/PRNewswire) - - Results to Include Nine-Month Data on TAXUS(R) Liberte(TM) Stent Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and press announcements at the Paris Course on Revascularization (EuroPCR), which runs from May ...
Vienna, Austria (ots/PRNewswire) - Bristol-Myers Squibb Company (NYSE: BMY) today announced 96-week clinical trial results demonstrating that entecavir maintains more viral load suppression compared to lamivudine in nucleoside-naive, chronic hepatitis B e-antigen-negative (HBeAg-) patients. Data ...
Basel, Switzerland (ots/PRNewswire) - - Important Step Towards Broad Access of Herceptin for Women With Aggressive Form of Breast Cancer Roche today announced that the European Union's Committee for Human Medicinal Products (CHMP) has issued a positive recommendation for the use of Herceptin following surgery and standard chemotherapy as adjuvant treatment ...
Madrid (ots/PRNewswire) - - Revenue Amounted to 14.8 Million Euros - Marketing Expenditure Increased 52.1% to 5.1 Million Euros - The Group Invested 11.8 Million Euros in Research and Development, Up 32% Zeltia S.A. (ZEL SM; ZEL MC) today presented its financial results for the first quarter of 2006, which showed a significant increase in Research & Development (R&D) spend, to 11.8 million euros. ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Company has signed an option agreement with Cellgate Inc. of Redwood City, California. This agreement allows Isotechnika the option to obtain an exclusive license to develop and commercialize conjugates consisting of Cellgate's patented transporter technology for the topical delivery of ...